RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 43 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 43

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Nantong University南通大学附属医院NantongHospital page
  2. Study siteAffiliated Hospital of North Sichuan Medical College川北医学院附属医院NanchongHospital page
  3. Study siteAffiliated Hospital of Southwest Medical University西南医科大学附属医院LuzhouHospital page
  4. Study siteBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page
  5. Study siteBeijing Youan Hospital, Capital Medical University首都医科大学附属北京佑安医院BeijingHospital page
  6. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  7. Study siteEastern Hepatobiliary Surgery Hospital海军军医大学第三附属医院(东方肝胆外科医院)ShanghaiHospital page
  8. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  9. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  10. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  11. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  12. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  13. Study siteFirst Affiliated Hospital of Xinjiang Medical University新疆医科大学第一附属医院UrumqiHospital page
  14. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  15. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  16. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  17. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  18. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  19. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  20. Study siteHunan Provincial People's Hospital湖南省人民医院(湖南师范大学附属第一医院)ChangshaHospital page
  21. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  22. Study siteLanzhou University Second Hospital兰州大学第二医院LanzhouHospital page
  23. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  24. Study siteMengchao Hepatobiliary Hospital of Fujian Medical University福建医科大学孟超肝胆医院FuzhouHospital page
  25. Study siteNantong Tumor Hospital南通市肿瘤医院NantongHospital page
  26. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  27. Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page
  28. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  29. Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page
  30. Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page
  31. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  32. Study siteShanghai Sixth People's Hospital上海市第六人民医院ShanghaiHospital page
  33. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  34. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
  35. Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
  36. Study siteThird Affiliated Hospital of Soochow University常州市第一人民医院ChangzhouHospital page
  37. Study siteThird Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院GuangzhouHospital page
  38. Study siteThird Xiangya Hospital中南大学湘雅三医院ChangshaHospital page
  39. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  40. Study siteTianjin Third Central Hospital天津市第三中心医院TianjinHospital page
  41. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  42. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  43. Study siteZhujiang Hospital南方医科大学珠江医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05862337, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Subjects with hepatocellular carcinoma (HCC) confirmed by histopathology or cytology or who meet the diagnostic criteria for Primary Liver Cancer 2022 or the American Association for the Study of Hepatology (AASLD) hepatocellular carcinoma.

    Inclusion criterion 2

  3. Subjects who received radical excision or ablation (Radio Frequency Ablation (RFA) or Microwave Ablation (MWA) only) within 4 to 12 weeks prior to randomization (multiple modalities or combined or multiple treatments are not acceptable).

    Inclusion criterion 3

    More than one surgical treatment for hepatocellular carcinoma; Received more than 1 prophylactic Transcatheter Arterial Chemoembolization (TACE) treatment after surgery; or received Hepatic Artery Infusion Chemotherapy (HAIC) therapy after surgery.

    Exclusion criterion 3

    Previous use of antiangiogenic drugs or PD-1, Programmed Cell Death-Ligand 1 (PD-L1) and other related immunotherapy drugs or systemic chemotherapy drugs.

    Exclusion criterion 4

  4. Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1; Predicted survival ≥12 weeks.

    Inclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05862337, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1; Predicted survival ≥12 weeks.
  • Subjects with hepatocellular carcinoma (HCC) confirmed by histopathology or cytology or who meet the diagnostic criteria for Primary Liver Cancer 2022 or the American Association for the Study of Hepatology (AASLD) hepatocellular carcinoma.
  • Subjects who received radical excision or ablation (Radio Frequency Ablation (RFA) or Microwave Ablation (MWA) only) within 4 to 12 weeks prior to randomization (multiple modalities or combined or multiple treatments are not acceptable).
  • No major vena portae 3 (Vp3) or vena portae 4 (Vp4) in the portal vein or any level of vascular invasion in the hepatic vein or inferior vena cava.
  • No extrahepatic metastasis.
  • High risk factors for recurrence after radical resection or complete ablation.
  • Complete recovery from surgical resection or ablation within 4 weeks before randomization.

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC histology.
  • Evidence of residual, recurrent, or metastatic disease at randomization.
  • More than one surgical treatment for hepatocellular carcinoma; Received more than 1 prophylactic Transcatheter Arterial Chemoembolization (TACE) treatment after surgery; or received Hepatic Artery Infusion Chemotherapy (HAIC) therapy after surgery.
  • Previous use of antiangiogenic drugs or PD-1, Programmed Cell Death-Ligand 1 (PD-L1) and other related immunotherapy drugs or systemic chemotherapy drugs.

Quoted from ClinicalTrials.gov, NCT05862337, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05862337, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05862337